Investigational treatment for acne appears promising in laboratory studies

Topical retinoids, which target retinoic acid receptors, are commonly used to treat acne. New research published in the British Journal of Dermatology reveals that trifarotene, a fourth-generation retinoid with potent and selective activity against only one particular retinoic acid receptor, may have an improved efficacy and safety profile compared with less selective retinoids.

Trifarotene is expected to result in low systemic levels, while retaining strong activity at the . This is likely to lead to reduced side effects.

"The pharmacological potency of trifarotene translates from in vitro models to topically treated human skin in vivo, resulting in the modulation of biological pathways that collectively are expected to translate into strong clinical efficacy in acne," said senior author Dr. Johannes Voegel, of Galderma R&D, in France. "As trifarotene is expected to be rapidly eliminated in the blood stream, this drug should be particularly useful for the treatment of large skin surface areas, including the back and chest of acne patients."


Explore further

Climbazole ups retinoid-linked biological activities

More information: J. Aubert et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-γ agonist trifarotene, British Journal of Dermatology (2018). DOI: 10.1111/bjd.16719
Journal information: British Journal of Dermatology

Provided by Wiley
Citation: Investigational treatment for acne appears promising in laboratory studies (2018, July 6) retrieved 23 July 2019 from https://medicalxpress.com/news/2018-07-treatment-acne-laboratory.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more